Goldstein: Expect More Litigation After Myriad

Goldstein: Expect More Litigation After Myriad Play

June 13 (Bloomberg Law) -- Tom Goldstein, partner at Goldstein & Russell, PC and founder of SCOTUSblog, talks with Bloomberg Law's Lee Pacchia about the United States Supreme Court's decision in the Association for Molecular Pathology v. Myriad Genetics, Inc. case. At issue was whether patents may be granted on parts of the human body. He also explores whether Justice Scalia's concurrence raises doubts whether he believes in molecular biology, and where patent litigation will head in the wake of the decision. Bloomberg Law is a sponsor of SCOTUSblog.

  • On Air Now

    Bloomberg Surveillance Watch Now

  • Next

    In The Loop with Betty Liu

blog comments powered by Disqus